Aurealis Therapeutics to strengthen its Board of Directors by appointing Laurent Décory

Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin and Roger Meier were elected to continue along with CEO Juha Yrjänheikki joining the Board. The timing of the nomination of Dr. Décory occurs in parallel with the company successfully completing the first safety cohort in the phase 1-2A diabetic foot ulcer clinical trial and advancing to repeated dosing cohorts.

Laurent brings to the company substantial experience and commercial leadership both in the Advanced Wound Care (AWC, Medtech) and Pharmaceutical industries. Laurent is the Managing Director of the company BlueJet Consulting, and recently served as Head, Global Commercial Excellence of Essity Health and Medical. Prior to that, Laurent was for 5 years Senior Vice-President, Global Commercial Excellence at BSN Medical in Hamburg. Previously, he held a variety of senior management and director roles at Takeda and Nycomed in Zurich, and Sanofi-Aventis and predecessor companies in Paris. Laurent has MSc. and PhD in Neurosciences & Pharmacology from University of Bordeaux and holds MBA from the ESSEC Business School, Paris.

“We are thrilled to welcome Laurent to our Board of Directors,” said Juha Yrjänheikki, CEO of Aurealis Therapeutics. “His vast commercial and strategic experience and leadership combined with scientific drive and understanding in the Medtech and Pharma industry are unique and impressive. We look forward to his contributions to the company as we are advancing in our phase 1-2A patient trials and need to think more and more about the commercial end-product and partnering/co-development.”

“I am very excited to join the Board of Aurealis Therapeutics,” said Dr. Décory. “Chronic wounds represent a major unmet medical need and a significant burden to patients and society. I look forward to working with my Board colleagues and with the entire staff and collaborators to bring this potentially game-changing technology into clinical proof-of-concept and commercialization. Moreover, I share the passion within Aurealis to expand this clinical grade drug product across a spectrum of regenerative and inflammatory indications.”

About AUP-16

AUP-16 is a genetically engineered Lactococcus lactis, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony stimulating factor (CSF1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of immune activating bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.

About Aurealis Therapeutics

Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage biopharmaceutical company focusing on the development of the clinical asset AUP-1602, the first-in-class four-in-one combination biologic drug for chronic wounds and other chronic inflammatory and degenerative diseases. The product is based on proprietary technology where genetically engineered lactic acid bacteria act as millions of small immune activating bioreactors in the human tissue and produce multiple human therapeutic proteins into the target tissue to effectively and safely re-educate the distorted host immune microenvironment to a proper state.

For more information:

Juha Yrjänheikki, CEO

Tel: +358 45 8433550

Email: juha(at)

Share the news:

other recent news: